Home / Join Newsletter / Careers / Contact Us
Soligenix

  • About Us
    • Company Overview
    • Leadership
  • Pipeline
    • Overview
    • Clinical Trials
    • BioTherapeutics
      • SGX301 – for the treatment of Cutaneous T-Cell Lymphoma
      • SGX203 – Oral BDP for Treating Pediatric Crohn’s Disease
      • SGX942 Oral Mucositis
      • SGX201 – Oral BDP for Preventing Acute Radiation Enteritis
    • Vaccines / BioDefense
      • ThermoVax® – Thermostability Technology
      • RiVax® Ricin Toxin Vaccine
      • OrbeShield® for Gastrointestinal Acute Radiation Syndrome (GI ARS)
      • SGX943 – Therapeutic Emerging Infectious Disease
    • Reference Literature
  • Investors
    • Fact Sheet (pdf)
    • SGX94 (Dusquetide) Executive Summary (pdf)
    • Analyst Coverage
    • SEC Filings
  • Partnering
    • In-Licensing
    • Out-Licensing
  • News & Events
    • Current Releases
    • Relevant Publications

SEC Filings

You are here: Investors > SEC Filings
0
0
0
0
0

Please visit the Soligenix page on XBRLFinancialWidget.com for SEC filings.


  • Investors
  • Fact Sheet (pdf)
  • SGX94 Executive Summary (pdf)
  • Analyst Coverage
  • SEC Filings
Legal Notice / Sitemap /
Website design by PING
Copyright © 2018 Soligenix Theme by: ThemeGrill Powered by: WordPress